Patients may not be receiving any other investigational agents
276.0
Patients receiving any other investigational agents
74.0
Patients receiving any other investigational agents
30.0
Patients who are receiving any other investigational agents
40.0
Patients may not be receiving any other investigational agents
107.0
Patients may not be receiving any other investigational agents
132.0
Patients who are receiving any other investigational agents
24.0
Patients who are receiving any other investigational agents are not eligible
110.0
Patients who are receiving any other anticancer or investigational agents
180.0
Patients should not be receiving any other investigational agents
165.0
Patients receiving any other investigational agents are ineligible
36.0
Patients who are actively receiving any other investigational agents
140.0
Patients should not be receiving any other investigational agents
68.0
Patients should not be receiving any other investigational agents
73.0
Patients may not be receiving any other investigational agents
80.0
Patients receiving any other investigational agents
72.0
Patients may not be receiving any other investigational agents
70.0
Patients who are receiving any other investigational agents
72.0
TUMOR BIOPSY SEQUENCING: Patients who are receiving any other investigational agents; patients on other trials will be eligible as long as they are no longer receiving study treatment
700.0
TREATMENT: Patients who are receiving any other investigational agents; patients on other trials will be eligible as long as they are no longer receiving study treatment
700.0
Patients who are receiving any other investigational agents
12.0
Patients who are receiving any other investigational agents
92.0
Patients who are receiving any other investigational agents
100.0
Patients who are receiving any other investigational therapy
40.0
Patients who are receiving any other therapeutic investigational agents
28.0
Patients who are receiving any other investigational agents
24.0
Patients who are receiving any other investigational agents
35.0
Patients receiving any other investigational agents are ineligible
40.0
Receiving any other investigational agents =< 28 days prior to registration
44.0
Patients who are receiving any other investigational agents
57.0
Patients may not be receiving any other investigational agents while on study
NONE
Patients receiving any other investigational agents are ineligible
23.0
Patients who are receiving any other investigational agents
80.0
Patients who are receiving any other investigational agents
37.0
Patients who are receiving any other investigational agents
66.0
Patients who are receiving any other investigational agents
12.0
Participants who are receiving any other investigational agents
42.0
Patients must not currently be receiving any other investigational agents
6452.0
Patients who are receiving any other investigational agents
58.0
Patients who are receiving any other investigational agents
30.0
Patients receiving any other investigational agents are ineligible
75.0
Patients who are receiving any other investigational agents
30.0
Patients may not be receiving any other investigational agents while on study treatment
126.0
Patients who are receiving any other investigational agents
46.0
Patients who are receiving any other investigational agents
35.0
Patients who are receiving any other investigational agents
82.0
Patients who are receiving any other investigational agents
37.0
Patients who are receiving any other investigational agents
50.0
Patients who are receiving any other investigational agents
46.0
Patients who are receiving any other investigational agents
15.0
Patients who are receiving any other investigational agents
46.0
Patients who are receiving any other investigational agents
36.0
Patients who are receiving any other investigational agents
90.0
Patients who are receiving any other investigational agents
45.0
Patients who are receiving any other biologic, cytotoxic or investigational agents
32.0
Participants who are receiving any other investigational agents
18.0
Patients who are receiving any other investigational agents for cancer
60.0
Patients receiving any other investigational agents
64.0
Patients who are receiving any other investigational agents
70.0
Patients who are receiving any other investigational agents
29.0
Patients who are receiving any other investigational agents
51.0
Patients must not be receiving any other investigational anti-cancer agents while on study
714.0
Patients who are receiving any other investigational agents
150.0
Patients who are receiving any other investigational agents
48.0
Patients who are receiving any other investigational agents
20.0
Participants who are receiving any other investigational agents
36.0
Patients who are receiving any other investigational agents
60.0
Patients who are receiving any other investigational agents
38.0
Patients who are receiving any other investigational agents
24.0
Patients who are receiving any other investigational agents
28.0
Patients who are receiving any other investigational agents
30.0
Patients who are receiving any other investigational agents
180.0
Participants who are receiving any other investigational agents
48.0
Patients who are receiving any other investigational agents
132.0
Patients who are receiving any other investigational agents
40.0
Patients who are receiving any other investigational agents
70.0
Patients receiving any other investigational agents are ineligible
30.0
Patients receiving any other investigational agents are ineligible
35.0
Patients who are currently receiving another investigational drug are not eligible
253.0
Patients who are currently receiving another investigational drug are not eligible
77.0
Patients who are currently receiving another investigational drug are not eligible
154.0
Patients who are currently receiving another investigational drug are not eligible
148.0
Patients who are currently receiving another investigational drug are not eligible
484.0
Patients who are receiving any other anti-cancer or investigational drug therapy are ineligible
110.0
Patients who are currently receiving another investigational drug are not eligible
67.0
Patients who are currently receiving another investigational drug
56.0
Investigational drugs: Patients who are currently receiving another investigational drug are not eligible
65.0
Patients who are currently receiving another investigational drug are not eligible
36.0
Patients who are receiving any other anticancer or investigational drug therapy are not eligible
25.0
Patients who are currently receiving another investigational drug are not eligible
146.0
Patients who are currently receiving another investigational drug are not eligible
51.0
Patients who are currently receiving another investigational drug
53.0
Patients who are currently receiving another investigational drug are not eligible
49.0
Patients who are currently receiving another investigational drug are not eligible
49.0
Patients who are currently receiving other anticancer agents are not eligible
253.0
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study
62.0
Patients who are currently receiving other anti-cancer agents are not eligible
77.0
Patients who are currently receiving other anti-cancer agents are not eligible
154.0
Currently receiving other anti-cancer agents
182.0
Patients who are currently receiving other anti-cancer agents are not eligible
484.0
Patients who are currently receiving other anti-cancer agents are not eligible
67.0
Patients who are currently receiving anti-platelet agents are not eligible
67.0
Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible
65.0
Patients who are currently receiving other anti-cancer agents are not eligible
36.0
Patients who are currently receiving other anti-cancer agents are not eligible
146.0
Patients who are currently receiving other anti-cancer agents are not eligible
51.0
Patients who are currently receiving other anti-cancer agents are not eligible
49.0
Patients who are currently receiving other anti-cancer agents are not eligible
49.0
Concomitant medications* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid * Investigational drugs: Patients who are currently receiving another investigational drug are not eligible* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible
81.0
Concomitant medications* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid* Investigational drugs: patients who are currently receiving another investigational drug are not eligible* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial* CYP3A/CYP3A4 agents: patients who are currently receiving drugs that are strong and moderate inducers or inhibitors of CYP3A or CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 21 days prior to enrollment to the end of the study
49.0
Concomitant medications* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid* Investigational drugs: patients who are currently receiving another investigational drug are not eligible* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial* CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or strong inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study** Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed
98.0
Concomitant medications* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid* Investigational drugs: patients who are currently receiving another investigational drug are not eligible* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial
144.0
Concomitant medications* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid* Investigational drugs: patients who are currently receiving another investigational drug are not eligible* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial* CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study* CYP2C19 agents: patients who are currently receiving drugs that are strong CYP2C19 inducers (e.g., rifampin, ritonavir) or inhibitors (e.g.., fluoxetine, fluvoxamine, ticlopidine) are not eligible
49.0
GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Concomitant medications* Corticosteroids: at the time of consent and enrollment to regimen specific subprotocols, patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment to the subprotocol will not be eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid* Investigational drugs: patients must meet criteria for prior therapy at the time of consent and enrollment to a subprotocol; other investigational agents may not be administered to patients while they are receiving study drug as part of a subprotocol * Anticancer agents: patients must meet criteria for prior therapy at the time of consent and enrollment to a subprotocol; other investigational agents may not be administered to patients while they are receiving study drug as part of a subprotocol * Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible
1500.0
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
102.0
Receiving any other investigational agent that would be considered as a treatment for the primary neoplasm
360.0
Receiving any other investigational agent
48.0
Receiving any other investigational agent
224.0
Receiving any other investigational agent that would be considered a treatment for the primary neoplasm
102.0
The participant has received any other type of investigational agent within 28 days before the first dose of study treatment
42.0
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
72.0
Prior investigational immunotherapy
80.0
Use of an investigational agent within the past 30 days
104.0
TREATMENT: Patients who have had prior treatment with any of the other investigational agents or combinations on this protocol are eligible but will not receive the same investigational agent (everolimus or trametinib) or combination (AZD1775/combination or veliparib/temozolomide); instead, patients will receive an investigational agent or combination prospectively identified to work on a different target in their tumorï¿½s mutation/aberrant pathway
700.0
Subjects must have received their last dose of investigational or biologic agent >= 7 days prior to study registration* In the event that a subject has received an investigational or biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to registration* If the investigational or biologic agent has a prolonged half-life (>= 7 days) then at least three (3) weeks must have elapsed prior to registration
52.0
Patients who are receiving any other concurrent investigational agents (patients are eligible to enroll 4 weeks after completion of prior agent)
54.0
Biologic therapy: patients should have received their last dose of biologic agent >= 7 days prior to enrollment; in the event the patient has received another biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to enrollment; if the investigational or biologic agent has a prolonged half-life then at least three (3) weeks interval is required
40.0
Patients must NOT receive concurrent anti-cancer therapy or investigational agent unless specified in protocol
600.0
Patients who are receiving any other investigational agent(s)
340.0
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
90.0
Patients who are currently participating in or have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment
36.0
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
135.0
Patients who are receiving any other investigational agents; if the patient received a previous investigational or other agent or treatment, a washout period of 4 weeks is required
35.0
Other investigational agent within 3 weeks prior to initiation of study therapy
30.0
No investigational agent within 21 days prior to registration
110.0
Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
50.0
Patient is receiving another investigational agent for the treatment of cancer
188.0
Patients who have previously received temsirolimus, another mTOR inhibitor, or any other investigational agent
337.0
Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
24.0
Patients may not be receiving any other investigational agents and may not have participated in a study of an investigational agent or using an investigational device within five half-lives of the compound or 3 months, whichever is greater
98.0
Patients who are receiving any other investigational agent
47.0
Patients may not have received any other investigational agents within 4 weeks of study entry
36.0
Have received any investigational new drug within the past 30 days or planning to receive such during the study period
240.0
Patients may not be planning to receive any other investigational agents
162.0
Participants who received investigational agents, other than investigational antiretroviral agents for HIV, within the 4 weeks before randomization, unless approved by the study chair
150.0
Patients who are receiving any other investigational agents or who have received pomalidomide in the past
63.0
Participants who received any other chronic (defined as more than 50% of the time in the last 6 months) systemic immunomodulatory agents (replacement doses of steroids for adrenal insufficiency are permitted or treatment with prednisone =< 5 mg/day); receipt of investigational agents within the 4 weeks before randomization enrollment, other than investigational antiretroviral agents for HIV and investigational or approved agents for hepatitis C, are also exclusionary
5058.0
Concurrent administration of any other investigational agents
23.0
Patients must not receive any other investigational agents while on study or within four weeks prior to registration
300.0
Participants who are receiving any other investigational agents within 4 weeks prior to enrollment; investigational antiretroviral agents for HIV are acceptable
56.0
Patients must not be planning to receive any other investigational agents during the course of protocol treatment
223.0
Patients must not receive any other investigational agents while on study or within four weeks prior to randomization
400.0
Use of any investigational product within 4 weeks prior to randomization
990.0
Patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeks
549.0
Any other investigational agents within the past 4 weeks
680.0
Patients should not have received any other investigational agents within the past 4 weeks
126.0
Patients who are receiving any other investigational agents; all investigational agents other than ibrutinib must have been discontinued at least 4 weeks prior to beginning treatment; prior ibrutinib therapy must have been discontinued at least 2 weeks prior to beginning therapy
50.0
Patients must not be receiving or planning to receive any other investigational agents
180.0
Concurrent anticancer therapy (including other investigational agents)
24.0
Concomitant therapy with any anticancer agents, immunosuppressive agents, other investigational anticancer therapies
84.0
Patients must not have received radiation therapy, non-cytotoxic agents or investigational agents or systemic corticosteroids within 14 days prior to registration
77.0
Participants should not have received any other investigational agents nor have participated in an investigational trial within the past 4 weeks
70.0
Patients who have not recovered from adverse events to < grade 1 (other than alopecia) due to agents administered more than 3 weeks earlier; however, the following therapies are allowed:* Hormone replacement therapy or oral contraceptives* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)* Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1
488.0
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier; however, the following therapies are allowed:* Hormone-replacement therapy or oral contraceptives* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)* Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1
40.0
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier; however, the following therapies are allowed:* Hormone-replacement therapy or oral contraceptives* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)
22.0
Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1
488.0
Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1
40.0
Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1
60.0
Patients who have received any other investigational agents within the past 28 days prior to cycle 1 day 1
90.0
Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1
22.0
Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1
78.0
